首页> 美国卫生研究院文献>PLoS Neglected Tropical Diseases >Immunogenicity and efficacy following sequential parenterally-administered doses of Salmonella Enteritidis COPS:FliC glycoconjugates in infant and adult mice
【2h】

Immunogenicity and efficacy following sequential parenterally-administered doses of Salmonella Enteritidis COPS:FliC glycoconjugates in infant and adult mice

机译:肠胃外连续剂量肠炎沙门氏菌COPS:FliC糖缀合物在婴儿和成年小鼠中的免疫原性和功效

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In sub-Saharan Africa, invasive nontyphoidal Salmonella (iNTS) infections with serovars S. Enteritidis, S. Typhimurium and I 4,[5],12:i:- are widespread in children < 5 years old. Development of an efficacious vaccine would provide an important public health tool to prevent iNTS disease in this population. Glycoconjugates of S. Enteritidis core and O-polysaccharide (COPS) coupled to the homologous serovar phase 1 flagellin protein (FliC) were previously shown to be immunogenic and protected adult mice against death following challenge with a virulent Malian S. Enteritidis blood isolate. This study extends these observations to immunization of mice in early life and also assesses protection with partial and full regimens. Anti-COPS and anti-FliC serum IgG titers were assessed in infant and adult mice after immunization with 1, 2 or 3 doses of S. Enteritidis COPS:FliC alone or co-formulated with aluminum hydroxide or monophosphoryl lipid A (MPL) adjuvants. S. Enteritidis COPS:FliC was immunogenic in both age groups, although the immune responses were quantitatively lower in infants. Kinetics of antibody production were similar for the native and adjuvanted formulations after three doses; conjugates formulated with MPL elicited significantly increased anti-COPS IgG titers in adult but not infant mice. Nevertheless, robust protection against S. Enteritidis challenge was seen for all three formulations when three doses were given either during infancy or as adults. We further found that significant protection could be achieved with two COPS:FliC doses, despite elicitation of modest serum anti-COPS IgG antibody titers. These findings guide potential immunization strategies that may be translated to develop a human pediatric iNTS vaccine for sub-Saharan Africa.
机译:在撒哈拉以南非洲,血清型沙门氏菌,鼠伤寒沙门氏菌和I 4,[5],12:i:-的侵袭性非伤寒沙门氏菌感染在5岁以下儿童中广泛存在。开发有效疫苗将为预防该人群中的iNTS疾病提供重要的公共卫生工具。先前已证明肠炎沙门氏菌核心和O-多糖(COPS)的糖共轭物与同源血清型1鞭毛蛋白(FliC)偶联具有免疫原性,并能保护成年小鼠免于死亡。这项研究将这些观察结果扩展到了生命早期的小鼠免疫,并且还评估了部分和全部方案的保护作用。在分别用1、2或3剂肠炎沙门氏菌COPS:FliC或与氢氧化铝或单磷酰脂质A(MPL)佐剂共同配制的婴儿和成年小鼠中评估抗COPS和抗FliC血清IgG滴度。肠炎沙门氏菌COPS:FliC在两个年龄组均具有免疫原性,尽管婴儿的免疫反应在数量上较低。在三剂后,天然和佐剂制剂的抗体产生动力学相似。用MPL配制的偶联物可在成年小鼠中引起抗COPS IgG滴度的显着提高,而未引起婴儿小鼠。然而,当在婴儿期或成年期给予三剂时,对于所有三种制剂都可以看到针对肠炎沙门氏菌攻击的强有力的保护作用。我们进一步发现,尽管诱发了适度的血清抗COPS IgG抗体滴度,但两次COPS:FliC剂量仍可实现显着的保护作用。这些发现指导了潜在的免疫策略,可以将其转化为开发针对撒哈拉以南非洲地区的人类儿科iNTS疫苗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号